Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

Derma Sciences reports higher Q1 net loss, provides guidance for 2015

Derma Sciences, Inc., a provider of products for management of acute and chronic wounds, has reported that net loss for the first quarter ended March 31, 2015 was $10.61 million, or $0.42 loss per share, compared to a net loss of $10.27 million, or $0.46 loss per share, for the same quarter ended March 31, 2014. For 2015, the company expects net sales to be around $88.1 million.

Published By MarketLine
26 May 2015
NewsWire
NewsWire

Halozyme Therapeutics reports lower Q1 net loss, reiterates guidance for 2015

Halozyme Therapeutics, Inc., a biotechnology company, has reported that net loss for the first quarter ended March 31, 2015 was $15.11 million, or $0.12 loss per share, compared to a net loss of $26.55 million, or $0.22 loss per share, for the same quarter ended March 31, 2014. For 2015, the company has reiterated its net revenue guidance range to be between $85 million and $95 million.

Published By MarketLine
26 May 2015
NewsWire
NewsWire

Sarepta Therapeutics Q1 net loss increases

Sarepta Therapeutics, Inc., a medical research and drug development company, has reported that net loss for the first quarter ended March 31, 2015 was $61.56 million, or $1.49 loss per share, compared to a net loss of $28.27 million, or $0.75 loss per share, for the same quarter ended March 31, 2014.

Published By MarketLine
26 May 2015
NewsWire
NewsWire

Stellar Biotechnologies Q2 net loss decreases

Stellar Biotechnologies, Inc. has reported that net loss for the second quarter ended March 31, 2015 was $426,164, or $0.01 loss per share, compared to a net loss of $1.43 million, or $0.02 loss per share, for the same quarter ended March 31, 2014.

Published By MarketLine
26 May 2015
NewsWire
NewsWire

Depomed reports net loss for Q1, updates guidance for 2015

Depomed, Inc., a specialty pharmaceutical company, has reported that net loss for the first quarter ended March 31, 2015 was $11.63 million, or $0.20 per diluted share, compared to a net income of $17.94 million, or $0.30 per diluted share, for the same quarter ended March 31, 2014. For 2015, the company has updated its non-GAAP adjusted earnings guidance range to be between $16 million and $28 million.

Published By MarketLine
26 May 2015
NewsWire
NewsWire

Repros Therapeutics Q1 net loss decreases

Repros Therapeutics Inc., a development stage biopharmaceutical company, has reported that net loss for the first quarter ended March 31, 2015 was $8.52 million, or $0.35 loss per share, compared to a net loss of $8.79 million, or $0.38 loss per share, for the same quarter ended March 31, 2014.

Published By MarketLine
26 May 2015
NewsWire
NewsWire

ImmuCell reports net income for Q1

ImmuCell Corporation, an animal health company, has reported that net income for the first quarter ended March 31, 2015 was $479,000, or $0.15 per diluted share, compared to a net loss of $13,000, or $0 per diluted share, for the same quarter ended March 31, 2014.

Published By MarketLine
26 May 2015
NewsWire
NewsWire

InSite Vision Q1 net loss decreases

InSite Vision Incorporated, a provider of ophthalmologic products, has reported that net loss for the first quarter ended March 31, 2015 was $828,000, or $0.01 loss per share, compared to a net loss of $4.68 million, or $0.04 loss per share, for the same quarter ended March 31, 2014.

Published By MarketLine
26 May 2015
NewsWire
NewsWire

Antares Pharma Q1 net loss decreases

Antares Pharma, Inc., a specialty pharmaceutical company, has reported that net loss for the first quarter ended March 31, 2015 was $6.79 million, or $0.05 loss per share, compared to a net loss of $8.79 million, or $0.07 loss per share, for the same quarter ended March 31, 2014.

Published By MarketLine
26 May 2015
NewsWire
NewsWire

Synta Pharmaceuticals Q1 net loss decreases

Synta Pharmaceuticals Corp., a biopharmaceutical company, has reported that net loss for the first quarter ended March 31, 2015 was $20.71 million, or $0.19 loss per share, compared to a net loss of $23.56 million, or $0.28 loss per share, for the same quarter ended March 31, 2014.

Published By MarketLine
26 May 2015

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.